Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC
Although GS-9674’s efficacy data don’t appear as promising as that for Intercept’s competing FXR agonist OCA, Gilead seems to be building an argument that its drug has a better combination of efficacy and safety.
You may also be interested in...
Gilead Hit With Another NASH Setback As Selonsertib Fails In First Phase III
Primary endpoint miss for Phase III selonsertib in cirrhotic NASH patients follows disappointing data at both 2018 major liver conferences. STELLAR-3 in NASH patients with bridging fibrosis looms large for Gilead’s hopes.
Q4 Pharma Earnings Preview: Roche, Celgene, Novo Nordisk, Merck, Gilead
Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.
Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis
As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…